Summary
Fifty-six patients with advanced metastatic carcinoma of the breast, melanoma and lymphoma were treated with the new vinca alkaloid vindesine in a prospective Phase II study. The dose was 3 mg/M2 by I.V. bolus once a week for a minimum of two doses. Patients who failed to respond to four I.V. doses were treated with 48-h intravenous infusions at a dose of 1.5 mg/M2 per 24 h.
Of the 26 evaluable patients with breast cancer, there were only two incomplete responses and four patients who experienced stabilization of disease. Of the 12 evaluable patients with melanoma, no responses were seen with four patients experiencing stabilization of disease. Of the 11 patients with non-Hodgkin's lymphomas, there was one complete remission which persisted for 26 months and two partial remissions. No additional responses were seen when the mode of administration was changed to 48-h infusion in three patients with breast cancer, five patients with melanoma and one patient with lymphoma. Significant toxicities included neutropenia in 24 patients and nausea and vomiting in two patients. There were no drug related deaths.
Previously reported experience with vindesine in these tumors is reviewed as well.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gralla RJ, Tan CTC, Young CW: Vindesine: a review of phase II trials. Cancer Chemother Pharmacol 2:271–274, 1979
Valdivieso M, Richman S, Burgess AM, Bodey CP, Freireich EJ: Initial clinical studies of vindesine. Cancer Treat Rep 65:873–875, 1981
Hoffman PC, Bitran JD, Golomb HM: Chemotherapy of metastatic non-small cell bronchogenic carcinoma. Semin Oncol 10:111–122, 1983
Livingston RB, Carter SK: Cancer Chemotherapy. Plenum Publishing, New York, 1970, pp 284–285
Livingston RB, Carter SK: Cancer Chemotherapy. Plenum Publishing, New York, 1970, pp 302–303
Yap HY, Blumenschein GR, Bodey GP, Hortobagyi GN, Buzdar AU and Distefano A: Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion. Cancer Treat Rep 65:775–779, 1981
Fleishman GB, Yap HY, Bodey GP, Chuang VP, Blumenschein GR: Comparability in therapeutic index with continuous 5-day infusion and 5-day bolus vindesine in the treatment of refractory breast cancer. (Abstract) Proc Am Soc Clin Oncol 1:82, 1982
Fraschini G, Yap HY, Barnes BC, Buzdar AU, Hortobagyi GN, Blumenschein GR: Continuous five-day infusion of vinblastine for refractory breast cancer. (Abstract) Proc Am Soc Clin Oncol 1:78, 1982
Miller TP, Jones SE, Chester A: Phase II trial of vindesine in the treatment of lymphomas, breast cancer, and other solid tumors. Cancer Treat Rep 64:1001–1003, 1980
Cobleigh MA, Williams SD, Einhorn LH: Phase II study of vindesine in patients with metastatic breast cancer. Cancer Treat Rep 65:659–663, 1981
Currie VE, Camacho F, Wittes R, Young C: Phase II evaluation of vindesine in patients with advanced breast cancer. Cancer Treat Rep 64:693–695, 1980
Valdivieso M, Bedikian AY, Bodey GP, Freireich EJ: Broad phase II study of vindesine. Cancer Treat Rep 65:877–879, 1981
Walker BK, Raich PC, Fontana J, Subramanian VP, Rogers JS, Knost JA, Denning B: Phase II study of vindesine in patients with advanced breast cancer. Cancer Treap Rep 66: 1729–1732, 1982
Smith IE, Hedley DW, Powles TJ, McElwain TJ: Vindesine: a phase II study in the treatment of breast carcinoma, malignant melanoma and other tumors. Cancer Treat Rep 62:1427–1433, 1978
Gad-El-Mawla N, Hamza MR, El-Serafi M, El-Khoudary A, Aboul-Einein M, El-Demerdash S: Phase II study of vindesine in patients with Hodgkin's disease, lymphoma and breast cancer. Cancer Treat Rep 67:316–317, 1983
Retsas S, Newton KA, Westbury G: Vindesine as a single agent in the treatment of advanced malignant melanoma. Cancer Chemother Pharmacol 2:257–260, 1979
Camacho FJ, Young CW, Wittes RE: Phase II trial of vindesine in patients with malignant melanoma. Cancer Treat Rep 64:179–181, 1979
Arseneau JC, Mellette SJ, Kuperminc M, Wolter J: Phase II study of vindesine in metastatic malignant melanoma. Cancer Treat Rep 65:355–356, 1981
Quagliana J, Stephens R, Baker L, Costanzi J: Vindesine in patients with metastatic malignant melanoma. (Abstract) Proc Am Soc Clin Oncol 1:182, 1982
Yap BS, Burgess MA, Benjamin RS, Bodey GP: Continous five day infusion of vindesine in the treatment of metastatic malignant melanoma. (Abstract) Proc Am Assoc Cancer Res 23:134, 1982
Bellet RE, Mastrangelo MJ, Berd D, Lustbader E: Chemotherapy of metastatic malignant melanoma. In Clark WH, Goldman LI, Mastrangelo MJ (eds): Human Malignant Melanoma. Grune and Stratton, 1979, pp 325–354
Sklaroff RB, Straus D, Young C: Phase II trial of vindesine in patients with malignant lymphoma. Cancer Treat Rep 63: 793–794, 1979
Mathé G, Misset JL, De Vassal F, Gouveia J, Hayat M, Machover D, Belpomme D, Pico JL, Schwarzenberg R, Ribaud P, Musset M, Jasmin C, Deluca L: Phase II trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma and Hodgkin's disease. Cancer Treat Rep 62:805–809, 1978
Bender RA, De Vita VT: Non-Hodgkin's lymphoma. In MJ Staquet (ed): Randomized Clinical Trials in Cancer: A Critical Review by Sites. Raven Press, New York, 1978, pp 77–102
Jones SE, Rosenberg SA, Kaplan HS, Kadin ME, Dorfman RF: Non-Hodgkin's lymphomas. II. Single agent chemotherapy. Cancer 30:31–38, 1972
Coltman CA: Chemotherapy of advanced Hodgkin's disease. Semin Oncol 7:155–173, 1980
Author information
Authors and Affiliations
Additional information
The views of the authors do not purport to reflect the positions of the Department of the Army or the Department of Defense.
Rights and permissions
About this article
Cite this article
DiBella, N.J., Berris, R., Garfield, D. et al. Vindesine in advanced breast cancer, lymphoma and melanoma. Invest New Drugs 2, 323–328 (1984). https://doi.org/10.1007/BF00175385
Issue Date:
DOI: https://doi.org/10.1007/BF00175385